- Conditions
- Kidney Transplantation
- Interventions
- CFZ533 - Cohort 1/Cohort 2, Mycophenolate Mofetil (MMF), Corticosteroids (CS), Tacrolimus, Induction therapy: basiliximab, Induction therapy: rabbit anti-thymocyte globulin (rATG), Maintenance population: EC-MPS, Maintenance population: MMF, Placebo 1 mL
- Biological · Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 418 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 15
- States / cities
- Los Angeles, California • San Francisco, California • Aurora, Colorado + 10 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1561–1584
of 7,459
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- imatinib mesylate, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 25 more
- Conditions
- Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD)
- Interventions
- Rozanolixizumab, Placebo
- Drug · Other
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 11
- States / cities
- Scottsdale, Arizona • Palo Alto, California • Aurora, Colorado + 8 more
- Conditions
- HIV Infections
- Interventions
- Indinavir sulfate, Ritonavir, Amprenavir, Nelfinavir mesylate, Efavirenz, Saquinavir
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2001 – 2004
- U.S. locations
- 8
- States / cities
- Palo Alto, California • Aurora, Colorado • Honolulu, Hawaii + 5 more
- Conditions
- ANCA-Associated Vasculitis
- Interventions
- Avacopan, Prednisone, Cyclophosphamide, Rituximab, Azathioprine
- Drug · Biological
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 331 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 41
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Los Angeles, California + 35 more
- Conditions
- Firearm Injury, Safety Issues
- Interventions
- Safe Storage Intervention, Safe Kids Medication
- Behavioral
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Nashville, Tennessee
- Conditions
- Myasthenia Gravis Crisis, Myasthenia Gravis Exacerbations, AChR Myasthenia Gravis
- Interventions
- Efgartigimod
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- HIV Infections
- Interventions
- Lamivudine, Stavudine, Zidovudine, Didanosine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 12 Years and older
- Enrollment
- 256 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1998
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 21 more
- Conditions
- Physician Fatigue
- Interventions
- SCS intervention schedule
- Other
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 413 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2017
- U.S. locations
- 6
- States / cities
- Aurora, Colorado • Iowa City, Iowa • Boston, Massachusetts + 3 more
- Conditions
- Type 1 Diabetes Mellitus-Type 2 Diabetes Mellitus
- Interventions
- Insulin aspart, NovoLog/NovoRapid, Insulin glargine (HOE901)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 597 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 42
- States / cities
- Little Rock, Arkansas • Concord, California • Escondido, California + 35 more
- Conditions
- Irritable Bowel Syndrome With Constipation, Functional Constipation
- Interventions
- Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers), Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers)
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 6 Years to 18 Years
- Enrollment
- 381 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 65
- States / cities
- Birmingham, Alabama • Foley, Alabama • Saraland, Alabama + 50 more
- Conditions
- Pancreatic Cancer, Hepatocellular Cancer, Mesothelioma, Breast Cancer, Gastric Cancer, Esophageal Cancer, Nasopharyngeal Cancer, Kidney Cancer, Squamous Cell Cancer of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Non-squamous
- Interventions
- TAK-500, Pembrolizumab, Tocilizumab, Dexamethasone
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Duarte, California • La Jolla, California + 9 more
- Conditions
- Thyroid Neoplasms
- Interventions
- AG013736
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 9
- States / cities
- Santa Monica, California • Aurora, Colorado • Denver, Colorado + 5 more
- Conditions
- Refractory Infantile Spasms
- Interventions
- JBPOS0101
- Drug
- Lead sponsor
- Bio-Pharm Solutions Co., Ltd.
- Industry
- Eligibility
- 6 Months to 36 Months
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 17
- States / cities
- Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 13 more
- Conditions
- Latrodectism
- Interventions
- Analatro, Saline
- Drug
- Lead sponsor
- Instituto Bioclon S.A. de C.V.
- Industry
- Eligibility
- 10 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 16
- States / cities
- Phoenix, Arizona • Davis, California • Fresno, California + 11 more
- Conditions
- Dyskinesia, Cerebral Palsy
- Interventions
- Placebo, Valbenazine
- Drug
- Lead sponsor
- Neurocrine Biosciences
- Industry
- Eligibility
- 6 Years to 70 Years
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 19
- States / cities
- San Diego, California • Aurora, Colorado • Stamford, Connecticut + 16 more
- Conditions
- Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
- Interventions
- Durvalumab, Laboratory Biomarker Analysis, Tremelimumab
- Biological · Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- Not listed
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1021
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 643 more
- Conditions
- Epilepsy, Temporal Lobe
- Interventions
- NRTX-1001
- Biological
- Lead sponsor
- Neurona Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2042
- U.S. locations
- 17
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Orange, California + 14 more
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma, Recurrent Cervical Carcinoma
- Interventions
- Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Laboratory Biomarker Analysis
- Drug · Other
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- Female only
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 26
- States / cities
- Aurora, Colorado • Chicago, Illinois • Urbana, Illinois + 17 more
- Conditions
- Primary IgA Nephropathy
- Interventions
- LNP023
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 540 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 16
- States / cities
- Glendale, Arizona • San Diego, California • San Dimas, California + 13 more
- Conditions
- Leukemia
- Interventions
- filgrastim, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, etoposide, leucovorin calcium, mercaptopurine, methotrexate, pegaspargase, therapeutic hydrocortisone, vincristine sulfate, radiation therapy
- Biological · Drug · Radiation
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 18 Months to 29 Years
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 135
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 116 more
- Conditions
- Relapsed/Refractory Acute Myeloid Leukemia
- Interventions
- NMS-03597812
- Drug
- Lead sponsor
- Nerviano Medical Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 7
- States / cities
- Duarte, California • Aurora, Colorado • Newark, Delaware + 4 more
- Conditions
- Multiple Sclerosis
- Interventions
- Tysabri® (natalizumab)
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- Not listed
- Enrollment
- 1,096 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 11
- States / cities
- Aurora, Colorado • Atlanta, Georgia • Cullman, Georgia + 8 more
- Conditions
- Immunization Rate
- Interventions
- Text Message Reminder/Recall, Parent Preference
- Behavioral
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 11 Years to 17 Years
- Enrollment
- 34,581 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Aurora, Colorado